Globally, Hepatitis C affects 130-150 million people. With antiviral medications, approximately 90% of those millions can be cured.
However, antiviral medications are costly, and even in developed countries many governments struggle with which medications should be subsidized and when. In Canadian patients suffering from Hepatitis C, a virus that causes liver disease and often worsens into a chronic condition, treatment can be expensive. Currently, Canadians with chronic HCV have limited access to Direct Anti-viral Agents (DAAs), the most effective existing treatment for the infection.